Literature DB >> 7723953

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

C G Goetz1, G T Stebbins.   

Abstract

We monitored 11 patients with advanced Parkinson's disease (PD) who entered nursing homes over a 5-year period and assessed chronicity of nursing home care, mortality, and hallucinatory status. Two years after the original study's close, none of these patients had ever been discharged from the nursing homes and all were dead. The mortality rate among the nursing home patients was significantly greater than that in 22 community-dwelling subjects with PD who were matched for age, gender, and disease duration. Hallucinatory status was generally stable; 82% of patients had the same hallucinatory status (presence or absence) at the two assessments. Four subjects from the original community-dwelling control group entered nursing homes during the follow-up period. Whereas motor and intellectual impairment scores were similar between these patients and the remaining 18 in the community, the presence of hallucinations was significantly greater among patients transferred to nursing homes. The study demonstrates the permanency of nursing home placement in advanced PD and the high mortality associated with such placement. It also documents the chronicity of hallucinatory behavior in these patients with advanced PD and reinforces our previously reported observations on the relationship between hallucinations and placement in chronic-care facilities.

Entities:  

Mesh:

Year:  1995        PMID: 7723953     DOI: 10.1212/wnl.45.4.669

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  66 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

3.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

4.  Quetiapine in the treatment of psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Mike Samuel; Anthony David
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 5.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 6.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

7.  Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Authors:  Kelsey A Holiday; Eva Pirogovsky-Turk; Vanessa L Malcarne; J Vincent Filoteo; Irene Litvan; Stephanie L Lessig; David Song; Dawn M Schiehser
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

8.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 9.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 10.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.